Top

Published in:

01-12-2018 | Research Article

To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [¹⁸F]FMISO-PET in Patients with Non-small Cell Lung Cancer

Authors: Li Li, Yuchun Wei, Yong Huang, Qingxi Yu, Wenju Liu, Shuqiang Zhao, Jinsong Zheng, Hong Lu, Jinming Yu, Shuanghu Yuan

Published in: Molecular Imaging and Biology | Issue 6/2018

Abstract

Purpose

To explore a representative hypoxic parameter to predict the treatment response and prognosis for [¹⁸F]fluoromisonidazole ([¹⁸F]FMISO) positron emission tomography (PET)/X-ray computed tomography (CT) in patients with non-small cell lung cancer (NSCLC).

Procedures

Twenty-nine patients with NSCLC underwent FMISO-PET scans before chemoradiotherapy (CRT). The maximum standard uptake values (SUVmax) in the tumor, normal lung, aortic arch, and vertical ridge muscle were measured, and the tumor-to-lung (T/L) ratios, tumor-to-blood (T/B) ratios, ands tumor-to-muscle (T/M) ratios were calculated and analyzed. Fractional hypoxic volume (FHV) was expressed as percentage of hypoxic volume.

Results

SUVmax, T/L ratio, T/B ratio, and FHV were all significantly different between the responders and the non-responders (SUVmax, 2.07 ± 0.53 vs. 2.61 ± 0.69, P = 0.026; T/L ratio, 3.16 ± 0.85 vs. 4.09 ± 1.46, P = 0.047; T/B ratio, 1.27 ± 0.20 vs. 1.48 ± 0.32, P = 0.042; 38.92 ± 18.47 vs. 52.91 ± 11.29 %, P = 0.020). However, the T/M ratio was not significantly different between the two populations (1.46 ± 0.31 vs. 1.67 ± 0.33, P = 0.098). The correlation ratio between hypoxic parameters and treatment responses ranged from high to low as FHV (r = 0.412); SUVmax (r = 0.400); T/L ratio (r = 0.379), P < 0.05; and T/B ratio (r = 0.355), P = 0.059. According to the area under curve (AUC) to predict response, the hypoxic parameters were arranged as FHV (AUC = 0.748), SUVmax (AUC = 0.731), T/L ratio (AUC = 0.719), and T/B ratio (AUC = 0.705). Binary logistic regression analyses showed that FHV was the only independent predictor for treatment response with the P value of 0.038. In the progression-free survival (PFS) prediction, both FHV and SUVmax reached statistical significance by Kaplan–Meier plots (FHV, 46.99 %, P = 0.010; SUVmax, 1.99, P = 0.046) while only FHV was the independent prognostic factor in multivariate analysis by Cox proportional hazard model (P = 0.037).

Conclusion

FHV may be a representative hypoxic parameter to predict the CRT response and PFS in patients with NSCLC.

Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408–1416PubMed

Chapman JD, Baer K, Lee J (1983) Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 43:1523–1528PubMed

Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts SA (2014) A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med 55:515–521CrossRef

Bollineni VR, Wiegman EM, Pruim J, Groen HJM, Langendijk JA (2012) Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy. Cancer Treat Rev 38:1027–1032CrossRef

Meng X, Kong FM, Yu J (2012) Implementation of hypoxia measurement into lung cancer therapy. Lung Cancer 75:146–150CrossRef

Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R (2005) Prognostic impact of hypoxia imaging with ¹⁸F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46:253–260PubMed

Li L, Yu J, Xing L, Ma K, Zhu H, Guo H, Sun X, Li J, Yang G, Li W, Yue J, Li B (2006) Serial hypoxia imaging with ^99mTc-HL91 SPECT to predict radiotherapy response in nonsmall cell lung cancer. Am J Clin Oncol 29:628–633CrossRef

Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, Grénman R, Minn H (2004) Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 59:971–982CrossRef

Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR, Krohn KA (2006) Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12:5435–5441CrossRef

10.

Tang G, Wang M, Tang X, Gan M, Luo L (2005) Fully automated one-pot synthesis of [¹⁸F]fluoromisonidazole. Nucl Med Biol 32:553–558CrossRef

11.

Grönroos T, Bentzen L, Marjamäki P et al (2004) Comparison of the biodistribution of two hypoxia markers [¹⁸F]FETNIM and [¹⁸F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 31:513–520CrossRef

12.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef

13.

Imamura Y, Azuma K, Kurata S, Hattori S, Sasada T, Kinoshita T, Okamoto M, Kawayama T, Kaida H, Ishibashi M, Aizawa H (2011) Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer 71:49–54CrossRef

14.

Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA, Griffin TW (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33:391–398CrossRef

15.

Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA (1996) Quantifying regional hypoxia in human tumors with positron emission tomography of [¹⁸F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36:417–428CrossRef

16.

Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA (2003) [¹⁸F]FMISO and [¹⁸F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30:695–704CrossRef

17.

Bollineni VR, Kerner GS, Pruim J et al (2013) PET imaging of tumor hypoxia using ¹⁸F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med 54:1175–1180CrossRef

18.

Hugonnet F, Fournier L, Medioni J, Smadja C, Hindie E, Huchet V, Itti E, Cuenod CA, Chatellier G, Oudard S, Faraggi M, for the Hypoxia in Renal Cancer (HYRC) Multicenter Group (2011) Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an ¹⁸F-fluoromisonidazole PET/CT study. J Nucl Med 52:1048–1055CrossRef

19.

Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, Kobayashi K, Watanabe S, Shiga T, Terasaka S, Kobayashi H, Kuge Y, Tamaki N (2016) ¹⁸F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. Eur J Nucl Med Mol Imaging 43:1469–1476CrossRef

20.

Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X, Pan L, Shao Z, Zhang Y, Liu G (2013) ¹⁸F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med 54:333–340CrossRef

21.

Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC, Krohn KA, Spence AM, Swanson KR (2009) Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 69:4502–4509CrossRef

22.

Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [¹⁸F]fluoromisonidazole and [¹⁸F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252CrossRef

23.

Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, Greco C, Mageras G, Pham HS, Larson SM, Ling CC, Humm JL (2008) Reproducibility of intratumor distribution of ¹⁸F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 70:235–242CrossRef

Title: To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer
Authors: Li Li
Yuchun Wei
Yong Huang
Qingxi Yu
Wenju Liu
Shuqiang Zhao
Jinsong Zheng
Hong Lu
Jinming Yu
Shuanghu Yuan
Publication date: 01-12-2018
Publisher: Springer International Publishing
Published in: Molecular Imaging and Biology / Issue 6/2018
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-018-1190-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [¹⁸F]FMISO-PET in Patients with Non-small Cell Lung Cancer

Abstract

Purpose

Procedures

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2018

Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis

Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy

Mass Spectrometry Imaging and Integration with Other Imaging Modalities for Greater Molecular Understanding of Biological Tissues

Imaging VEGF Receptors and αvβ3 Integrins in a Mouse Hindlimb Ischemia Model of Peripheral Arterial Disease

Metabolic and Molecular Imaging with Hyperpolarised Tracers

In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer